Literature DB >> 2848851

In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase.

L Ossowski1.   

Abstract

The ability of the chick embryo chorioallantoic membrane (CAM) to withstand invasion by tumor cells can be intentionally compromised by altering its morphological integrity. Using a newly developed quantitative assay of invasion we showed that intact CAMs were completely resistant to invasion by tumor cells, wounded CAMs did not pose a barrier to penetration, and CAMs that were wounded and then allowed to reseal displayed partial susceptibility to invasion. The invasion of resealed CAMs required catalytically active plasminogen activator (PA) of the urokinase type (uPA); the invasive efficiency of tumor cells was reduced by 75% when tumor uPA activity or tumor uPA production was inhibited. The invasive ability of human tumor cells, which have surface uPA receptors but which do not produce the enzyme, could be augmented by saturating their receptors with exogenous uPA. The mere stimulation of either uPA or tissue plasminogen activator production, in absence of binding to cell receptors, did not result in an enhancement of invasiveness. These findings suggest that the increased invasive potential of tumor cells is correlated with cell surface-associated proteolytic activity stemming from the interaction between uPA and its surface receptor.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2848851      PMCID: PMC2115626          DOI: 10.1083/jcb.107.6.2437

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  49 in total

1.  The human tumor grown in the egg.

Authors:  J J HARRIS
Journal:  Ann N Y Acad Sci       Date:  1958-12-05       Impact factor: 5.691

2.  Heat-regulated expression of the hepatitis B virus surface antigen in the human Wish cell line.

Authors:  M Dreano; X Fouillet; J Brochot; J M Vallet; M L Michel; D Rungger; P Bromley
Journal:  Virus Res       Date:  1987-07       Impact factor: 3.303

3.  Transepithelial invasion and intramesenchymal infiltration of the chick embryo chorioallantois by tumor cell lines.

Authors:  P B Armstrong; J P Quigley; E Sidebottom
Journal:  Cancer Res       Date:  1982-05       Impact factor: 12.701

4.  Invasion of an artificial blood vessel wall by human fibrosarcoma cells.

Authors:  P A Jones; H B Neustein; F Gonzales; E Bogenmann
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

5.  Cells transformed by temperature-sensitive mutants of avian sarcoma virus cause tumors in vivo at permissive and nonpermissive temperatures.

Authors:  G Poste; M K Flood
Journal:  Cell       Date:  1979-08       Impact factor: 41.582

6.  Antibodies to plasminogen activator inhibit human tumor metastasis.

Authors:  L Ossowski; E Reich
Journal:  Cell       Date:  1983-12       Impact factor: 41.582

7.  Migrating keratinocytes express urokinase-type plasminogen activator.

Authors:  S Morioka; G S Lazarus; J L Baird; P J Jensen
Journal:  J Invest Dermatol       Date:  1987-04       Impact factor: 8.551

8.  The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type.

Authors:  E F Plow; D E Freaney; J Plescia; L A Miles
Journal:  J Cell Biol       Date:  1986-12       Impact factor: 10.539

9.  Plasminogen activator and mouse spermatozoa: urokinase synthesis in the male genital tract and binding of the enzyme to the sperm cell surface.

Authors:  J Huarte; D Belin; D Bosco; A P Sappino; J D Vassalli
Journal:  J Cell Biol       Date:  1987-05       Impact factor: 10.539

10.  Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts.

Authors:  J Pöllänen; K Hedman; L S Nielsen; K Danø; A Vaheri
Journal:  J Cell Biol       Date:  1988-01       Impact factor: 10.539

View more
  68 in total

1.  Formation of polyomavirus-like particles with different VP1 molecules that bind the urokinase plasminogen activator receptor.

Authors:  Young C Shin; William R Folk
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

Review 2.  The plasminogen activator/plasmin system.

Authors:  J D Vassalli; A P Sappino; D Belin
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

3.  Independence of metastatic ability and extravasation: metastatic ras-transformed and control fibroblasts extravasate equally well.

Authors:  S Koop; E E Schmidt; I C MacDonald; V L Morris; R Khokha; M Grattan; J Leone; A F Chambers; A C Groom
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

4.  Alpha 2-macroglobulin restricts plasminogen activation to the surface of RC2A leukemia cells.

Authors:  R W Stephens; H Tapiovaara; T Reisberg; J Bizik; A Vaheri
Journal:  Cell Regul       Date:  1991-12

5.  Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation.

Authors:  P H Quax; N Pedersen; M T Masucci; E J Weening-Verhoeff; K Danø; J H Verheijen; F Blasi
Journal:  Cell Regul       Date:  1991-10

6.  Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism.

Authors:  Kenneth A Botkjaer; Elena I Deryugina; Daniel M Dupont; Henrik Gårdsvoll; Erin M Bekes; Cathrine K Thuesen; Zhuo Chen; Zhou Chen; Michael Ploug; James P Quigley; Peter A Andreasen
Journal:  Mol Cancer Res       Date:  2012-10-04       Impact factor: 5.852

7.  Dual function of pancreatic endoplasmic reticulum kinase in tumor cell growth arrest and survival.

Authors:  Aparna C Ranganathan; Shishir Ojha; Antonis Kourtidis; Douglas S Conklin; Julio A Aguirre-Ghiso
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

8.  An autocrine role for urokinase in phorbol ester-mediated differentiation of myeloid cell lines.

Authors:  A R Nusrat; H A Chapman
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

9.  Time and dose dependency of the suppression of pulmonary metastases of rat mammary cancer by amiloride.

Authors:  D M Evans; K Sloan-Stakleff; M Arvan; D P Guyton
Journal:  Clin Exp Metastasis       Date:  1998-05       Impact factor: 5.150

10.  Sites of urokinase-type plasminogen activator expression and distribution of its receptor in the normal human kidney.

Authors:  S N Wagner; M J Atkinson; C Wagner; H Höfler; M Schmitt; O Wilhelm
Journal:  Histochem Cell Biol       Date:  1996-01       Impact factor: 4.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.